ETPrime

Mangalam Drugs and Organics Share Price

  • 74.960.69 (0.93%)
  • Volume: 0
  • Pre Open
  • Last Updated On: 24 Sep, 2025, 03:42 PM IST
STOCK SCORE
ETPrime Only
High: "NaN",Open: "NaN",Low: "NaN",
  • 1D
  • 1W
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Loading...
Mangalam Drugs and Organics Share Price
  • 74.960.69 (0.93%)
  • Volume: 0
Advertisment

Key Metrics

PE Ratio
(x)		-12.04
EPS - TTM
(₹)		-6.17
MCap
(₹ Cr.)		117.56
Sectoral MCap Rank
102
PB Ratio
(x)		0.79
Div Yield
(%)		0.00
Face Value
(₹)		10.00
Beta

Beta

1 Month1.34
3 Months0.01
6 Months0.78
1 Year0.90
3 Years1.43

1.34
VWAP
(₹)		0.00
52W H/L
(₹)
132.00 / 70.10

Mangalam Drugs share price insights

  • Company has spent 4.69% of its operating revenues towards interest expenses and 12.75% towards employee cost in the year ending Mar 31, 2025. (Source: Consolidated Financials)

  • Mangalam Drugs and Organics Ltd. share price moved up by 0.93% from its previous close of Rs 74.27. Mangalam Drugs and Organics Ltd. stock last traded price is 74.96

    Share PriceValue
    Today/Current/Last74.96
    Previous Day74.2775.04

InsightsMangalam Drugs

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Mangalam Drugs Share Price Returns

    1 Day0.93%
    1 Week-0.09%
    1 Month-7.01%
    3 Months-6.1%
    1 Year-39.73%
    3 Years-51.05%
    5 Years-44.6%

    ET Stock ScreenersTop Score Companies

    Check whether Mangalam Drugs belongs to analysts' top-rated companies list?

    View Stock Screeners

    Mangalam Drugs News & Analysis

    View all Mangalam Drugs Share News & Announcements

    Mangalam Drugs Share Analysis

    Unlock Stock Score, Analyst' Ratings & Recommendations

    Share Analysis Non Prime User
    • View Stock Score on a 10-point scale
    • See ratings on Earning, Fundamentals, Valuation, Risk & Price
    • Check stock performance
    JOIN ET PRIME

    Mangalam Drugs Share Recommendations

    No Recommendations details available for this stock.
    Check out other stock recos.

    Mangalam Drugs Financials

    • Insights

      • Employee & Interest Expense

        Company has spent 4.69% of its operating revenues towards interest expenses and 12.75% towards employee cost in the year ending Mar 31, 2025. (Source: Consolidated Financials)
      Quarterly | AnnualJun 2025Mar 2025Dec 2024Sep 2024Jun 2024
      Total Income57.3573.2588.8580.0876.56
      Total Income Growth (%)-21.71-17.5610.954.60-25.15
      Total Expenses66.3067.5883.9975.2172.22
      Total Expenses Growth (%)-1.90-19.5411.674.14-23.49
      EBIT-8.955.664.864.874.33
      EBIT Growth (%)-258.0616.67-0.2112.29-45.01
      Profit after Tax (PAT)-13.800.061.292.692.68
      PAT Growth (%)0.00-95.38-52.160.20-23.95
      EBIT Margin (%)-15.617.735.466.085.66
      Net Profit Margin (%)-24.060.081.453.363.51
      Basic EPS (₹)-8.720.040.811.701.70
      Quarterly | AnnualJun 2025Mar 2025Dec 2024Sep 2024Jun 2024
      Total Income57.3573.2588.8480.0876.56
      Total Income Growth (%)-21.71-17.5510.944.60-25.15
      Total Expenses66.2367.4983.8775.2272.22
      Total Expenses Growth (%)-1.87-19.5311.514.15-23.49
      EBIT-8.885.764.974.864.33
      EBIT Growth (%)-254.3315.792.2612.20-45.07
      Profit after Tax (PAT)-13.730.151.402.692.68
      PAT Growth (%)0.00-89.24-47.780.05-24.29
      EBIT Margin (%)-15.497.865.606.075.66
      Net Profit Margin (%)-23.940.211.583.353.51
      Basic EPS (₹)-8.670.100.891.701.70
      Quarterly | Annual FY 2025
      Total Revenue318.73
      Total Revenue Growth (%)-13.55
      Total Expenses313.95
      Total Expenses Growth (%)-17.33
      Profit after Tax (PAT)6.72
      PAT Growth (%)-
      Operating Profit Margin (%)6.19
      Net Profit Margin (%)2.11
      Basic EPS (₹)4.25
      Quarterly | Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Revenue318.73368.69372.69451.16384.86
      Total Revenue Growth (%)-13.55-1.07-17.3917.2335.74
      Total Expenses313.74379.75370.47423.42345.34
      Total Expenses Growth (%)-17.382.50-12.5122.6124.55
      Profit after Tax (PAT)6.92-9.051.2719.6627.97
      PAT Growth (%)--812.51-93.54-29.72238.94
      Operating Profit Margin (%)6.260.774.028.6212.84
      Net Profit Margin (%)2.17-2.450.344.357.35
      Basic EPS (₹)4.37-5.720.8012.4217.67

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2025
      Total Assets366.42
      Total Assets Growth (%)9.81
      Total Liabilities217.44
      Total Liabilities Growth (%)9.87
      Total Equity148.98
      Total Equity Growth (%)9.71
      Current Ratio (x)1.04
      Total Debt to Equity (x)0.54
      Contingent Liabilities0.00
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Assets359.24357.14359.63328.43262.85
      Total Assets Growth (%)0.59-0.699.5024.9513.95
      Total Liabilities210.58214.80207.67177.86131.89
      Total Liabilities Growth (%)-1.963.4316.7634.854.07
      Total Equity148.66142.35151.96150.56130.96
      Total Equity Growth (%)4.43-6.320.9314.9726.00
      Current Ratio (x)1.081.101.251.401.23
      Total Debt to Equity (x)0.550.620.450.480.44
      Contingent Liabilities0.007.1826.336.269.61

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2025
      Net Cash flow from Operating Activities42.59
      Net Cash used in Investing Activities-19.47
      Net Cash flow from Financing Activities-21.71
      Net Cash Flow1.41
      Closing Cash & Cash Equivalent2.59
      Closing Cash & Cash Equivalent Growth (%)119.47
      Total Debt/ CFO (x)1.91
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Net Cash flow from Operating Activities42.9212.1739.5225.7127.55
      Net Cash used in Investing Activities19.47-17.91-22.17-27.33-31.29
      Net Cash flow from Financing Activities-21.715.70-16.622.982.70
      Net Cash Flow42.26-0.040.731.36-1.04
      Closing Cash & Cash Equivalent43.261.002.681.950.59
      Closing Cash & Cash Equivalent Growth (%)4,230.11-62.7337.69228.98-63.67
      Total Debt/ CFO (x)1.897.231.732.812.11

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2025
      Return on Equity (%)4.51
      Return on Capital Employed (%)11.27
      Return on Assets (%)1.83
      Interest Coverage Ratio (x)2.43
      Asset Turnover Ratio (x)0.91
      Price to Earnings (x)17.48
      Price to Book (x)0.79
      EV/EBITDA (x)5.40
      EBITDA Margin (%)11.41
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Return on Equity (%)4.65-6.350.8313.0521.35
      Return on Capital Employed (%)11.411.627.7019.6131.47
      Return on Assets (%)1.92-2.530.355.9810.64
      Interest Coverage Ratio (x)2.431.262.044.406.22
      Asset Turnover Ratio (x)0.891.031.081.531.54
      Price to Earnings (x)16.98-16.23123.468.295.63
      Price to Book (x)0.791.031.021.081.20
      EV/EBITDA (x)5.4013.358.504.743.70
      EBITDA Margin (%)11.404.746.9710.8915.26

    Financial InsightsMangalam Drugs

    • Income (P&L)

      • Employee & Interest Expense

        Company has spent 4.69% of its operating revenues towards interest expenses and 12.75% towards employee cost in the year ending Mar 31, 2025. (Source: Consolidated Financials)

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Mangalam Drugs Technicals

    • Stock doesn't have any Buy/Sell Signals.

    • Price Analysis Data details are not available.

    • Pivot Levels

      R1R2R3PIVOTS1S2S3
      Classic-------

      Average True Range

      5 DAYS14 DAYS28 DAYS
      ATR---

    Mangalam Drugs Peer Comparison

      • CHART
      • TABLE

      • Choose from Peers

          Choose from Stocks

          • 1D
          • 1W
          • 1M
          • 3M
          • 6M
          • 1Y
          • 5Y
          Loading...

        • Ratio Performance

          NAMEP/E (x)P/B (x)ROE %ROCE %ROA %Rev CAGR [3Yr]OPMNPMBasic EPSCurrent RatioTotal Debt/ Equity (x)Total Debt/ CFO (x)
          Mangalam Drugs-12.040.794.5111.271.83-10.836.192.114.251.040.541.91
          Natural Capsule-40.240.870.262.850.147.605.380.360.231.300.453.88
          Aarey Drugs52.661.582.907.151.68-0.782.130.841.842.200.253.61
          Alpa Labs7.471.1411.3714.728.763.3123.0317.349.344.100.000.00
          Krebs Biochem-6.05-10.090.00-32.07-15.93-10.14-48.50-62.19-12.490.10-0.56-10.42
          Add More
          Annual Ratios (%)

          Choose from Peers

          • Par Drugs & Chemical
          • Bal Pharma
          • Vaishali Pharma
          • Ind Swift Ltd
          • Biofil Chem

          Choose from Stocks

            See All Parameters

          Peers InsightsMangalam Drugs

            Do you find these insights useful?

            • hate it

            • meh

            • love it

            Mangalam Drugs Shareholding Pattern

            • Loading...
              Showing Mangalam Drugs Shareholding as on Jun 2025
              CategoryJun 2025Mar 2025Dec 2024Sep 2024
              Promoters50.3050.3050.3050.30
              Pledge13.2313.2311.0110.26
              FII0.530.470.110.11
              DII0.000.000.000.00
              Mutual Funds0.000.000.000.00
              Others49.1749.2349.5949.59
            • Showing Shareholding as on Jun 2025
              CategoryNo. of SharesPercentage% Change QoQ
              Promoters79,62,04650.30 %0.00
              Pledge10,53,00013.23 %0.00
              FII84,4980.53 %0.06
              Others77,81,70449.17 %-0.06

            Mangalam Drugs MF Ownership

            MF Ownership details are not available.

            Top Searches:
            Mangalam Drugs News Mangalam Drugs Quarterly Results Mangalam Drugs Dividend Mangalam Drugs Q1 ResultsMangalam Drugs Q2 ResultsMangalam Drugs Q3 ResultsMangalam Drugs Q4 Results

            Mangalam Drugs Corporate Actions

            • Meeting DateAnnounced onPurposeDetails
              Sep 29, 2025Sep 09, 2025AGM-
              Sep 05, 2025Aug 28, 2025Board MeetingOthers
              Aug 12, 2025Jul 14, 2025COM-
              Aug 07, 2025Jul 31, 2025Board MeetingQuarterly Results & Others
              May 17, 2025May 14, 2025Board MeetingAudited Results
            • TypeDividendDividend per ShareEx-Dividend DateAnnounced on
              Interim5%0.5Dec 21, 2017Dec 12, 2017
              Final 2%0.2Sep 19, 2006Jul 04, 2006
              Final 2%0.2Aug 30, 2005Jun 13, 2005

            • No other corporate actions details are available.

            About Mangalam Drugs

            Mangalam Drugs and Organics Ltd., incorporated in the year 1972, is a Small Cap company (having a market cap of Rs 117.56 Crore) operating in Pharmaceuticals sector. Mangalam Drugs and Organics Ltd. key Products/Revenue Segments include Pharmaceuticals, Trading Income, Service Charges, Other Operating Revenue and Scrap for the year ending 31-Mar-2024. Show More

            • Executives

            • Auditors

            • GM

              Govardhan Murlidhar Dhoot

              Chairman & Managing Director
              BM

              Brijmohan Murlidhar Dhoot

              Whole Time Director
              RK

              Rakesh Kishinchand Milwani

              Non Exe.Non Ind.Director
              NS

              Nidhi Shantanu Mundada

              Independent Director
              Show More
            • V S Somani & Co.
              Batliboi & Purohit

            Industry

            Pharma - Indian

            Key Indices Listed on

            -

            Address

            Rupam Building, 3rd Floor,239, P.D. Mello Road,Near GPO,Mumbai, Maharashtra - 400001

            Contact

            [email protected]

            http://www.mangalamdrugs.com

            More Details

            FAQs about Mangalam Drugs share

            • 1. What's the Mangalam Drugs share price today?
              As on 24 Sep, 2025, 03:42 PM IST Mangalam Drugs share price is down by 0.69% basis the previous closing price of Rs 75.05. Mangalam Drugs share price is Rs 74.27. Return Performance of Mangalam Drugs Shares:
              • 1 Week: Mangalam Drugs share price moved down by 1.14%
            • 2. What is Mangalam Drugs's 52 week high / low?
              Mangalam Drugs share price saw a 52 week high of Rs 132.00 and 52 week low of Rs 70.10.
            • 3. What are the returns for Mangalam Drugs share?
              Return Performance of Mangalam Drugs Shares:
              • 1 Week: Mangalam Drugs share price moved down by 1.14%
            • 4. What is the PE & PB ratio of Mangalam Drugs?
              The PE ratio of Mangalam Drugs stands at -12.12, while the PB ratio is 0.79.
            • 5. What is the market cap of Mangalam Drugs?
              Market Capitalization of Mangalam Drugs stock is Rs 117.56 Cr.

            Trending in Markets

            Top Gainers As on 03:59 PM | 24 Sep 2025

            Tata Investment8,863.50
            725.50 (8.92%)
            Minda Corp.579.10
            44.61 (8.35%)
            Syrma SGS Technology858.40
            40.50 (4.96%)
            SCI232.48
            9.14 (4.10%)
            Deepak Fertilisers1,580.30
            61.71 (4.07%)

            Top Losers As on 03:59 PM | 24 Sep 2025

            Adani Power144.50
            -17.85 (-11.00%)
            Adani Gas667.30
            -55.66 (-7.70%)
            Balrampur Chini469.70
            -26.56 (-5.36%)
            Zen Tech1,533.20
            -70.30 (-4.39%)
            Godrej Properties2,019.10
            -84.60 (-4.03%)

            DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

            DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

            By using this site, you agree to the Terms of Service and Privacy Policy.

            Business News›Markets›Stocks›Stock Price Quotes›Mangalam Drugs Share Price
            The Economic Times
            BrowseCompanies: